Objective:

To present early results of the iDose TREX, an extended-release travoprost implant, in reducing intraocular pressure (IOP) in glaucoma patients.

Approach:

Key Findings:

• Mean IOP at baseline was 24.3 mmHg.
• At day 11, IOP dropped by 44% (10.8 mmHg).
• At week 6, IOP reduction was 37%.
• No adverse events were reported.

Interpretation:

The iDose TREX shows promising early results in significantly reducing IOP without adverse effects, indicating its potential as a viable treatment option for glaucoma.

Limitations:

• Small sample size of only 10 patients.
• Early follow-up duration may not capture long-term efficacy and safety.

Conclusion:

The iDose TREX represents a significant advancement in glaucoma treatment, with early data suggesting effective IOP reduction and safety.

Sources:

• American Glaucoma Society Meeting 2026
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.